Researchers Find Rituximab Promotes Long-Term Response for Patients with Immune Destruction of Platelets
May 14, 2012
A new analysis concludes that rituximab, a drug commonly used to treat blood cancers, leads to treatment responses lasting at least five years in approximately one quarter of patients with low platelet counts and a risk of bleeding due to chronic immune thrombocytopenic purpura (ITP).